<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105633</url>
  </required_header>
  <id_info>
    <org_study_id>CT21028</org_study_id>
    <nct_id>NCT05105633</nct_id>
  </id_info>
  <brief_title>Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke</brief_title>
  <acronym>POST-ETERNAL</acronym>
  <official_title>Extending the Time Window for Tenecteplase by Effective RecanalizatioN of bAsilar Artery occLusion in Patients With POSTerior Circulation Stroke (POST-ETERNAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Melbourne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting to the emergency department with an acute ischemic stroke due to basilar&#xD;
      artery occlusion within 24 hours of stroke onset will be assessed to determine their&#xD;
      eligibility for randomization into the trial. If the patient gives informed consent they will&#xD;
      be randomised 50:50 using a central computerised allocation process to either standard of&#xD;
      care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or&#xD;
      tenecteplase 0.25mg/kg before undergoing mechanical thrombectomy as required at treating&#xD;
      clinician's discretion. The trial is Multi-arm, Multi-stage, prospective, randomised,&#xD;
      open-label, blinded endpoint (PROBE) design with seamless phase 2b/3 transition if the&#xD;
      intermediate endpoint (recanalization without symptomatic intracerebral hemorrhage) is met in&#xD;
      analysis of the first 202 patients. Adaptive sample size re-estimation (Mehta and Pocock)&#xD;
      will be performed when 240 patients have completed 3 month follow-up (minimum sample size&#xD;
      320, maximum sample size 688).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Multi-Arm Multi-Stage (MAMS), multiregional, multicentre, prospective,&#xD;
      randomised, open-label, blinded endpoint (PROBE), controlled seamless phase 2b/3 trial (2 arm&#xD;
      with 1:1 randomisation) with adaptive sample size recalculation in patients with stroke due&#xD;
      to basilar artery occlusion. Stage 1 will use the surrogate outcome of recanalization without&#xD;
      symptomatic intracerebral hemorrhage (sICH) to establish whether proceeding to Stage 2 is&#xD;
      warranted. If results in the first n= 202 patients meet success criteria, the trial will&#xD;
      seamlessly convert to a phase 3 design using modified Rankin scale 0-1 at 3 months as the&#xD;
      primary outcome (minimum n=320 with interim sample size re-estimation at n=240, maximum&#xD;
      sample n=688) using the Mehta and Pocock conditional power method. Each regionally-based&#xD;
      stratum will be pooled in the final analysis and analysed as a stratification by geographic&#xD;
      region. Randomisation of patients within each stratum will be stratified by the&#xD;
      investigator's intention to treat with mechanical thrombectomy (or not) and the&#xD;
      investigator's intention to treat with alteplase intravenous thrombolysis should the patient&#xD;
      be randomised to the control group (or not). Covariate adjusted minimum sufficient balance&#xD;
      randomisation will then be applied to control for age, NIHSS and time from&#xD;
      onset-to-randomisation (dichotomized as 0-6 hours vs 6-24 hours). The primary objective of&#xD;
      the study is to test the hypothesis that the thrombolytic tenecteplase (TNK, 0.25mg/kg) ±&#xD;
      mechanical thrombectomy administered within 24 hours after symptoms onset, is superior to&#xD;
      current best practice (alteplase, rtPA, 0.9mg/kg or standard care/no lysis ± mechanical&#xD;
      thrombectomy) in achieving excellent functional outcome (mRS 0-1) or return to the premorbid&#xD;
      modified Rankin Scale at 90 days in patients with acute ischemic stroke due to basilar artery&#xD;
      occlusion. Estimated study duration is 5 years. Patients will participate in the trial for 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will receive either intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) or standard of care (alteplase 0.9mg/kg or no lysis) +/- mechanical thrombectomy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 2- Primary outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS (if baseline premorbid mRS 2-3) at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale 0-2 or return to baseline mRS at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients with Modified Rankin Scale 0-2 or return to baseline mRS at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale 0-3 or return to baseline mRS at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients with Modified Rankin Scale 0-3 or return to baseline mRS at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal analysis of the mRS at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal analysis of the mRS, merging category 5-6, at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substantial reperfusion on initial digital subtraction angiography run prior to thrombectomy</measure>
    <time_frame>Initial angiogram (day 0)</time_frame>
    <description>Proportion of patients with complete occlusion at baseline who achieve eTICI 2b/3 on initial digital subtraction angiography run prior to thrombectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment (EQ-5D) - at 90 days and 12 months</measure>
    <time_frame>90 days and 12 months</time_frame>
    <description>Quality of Life assessment (EQ-5D) - at 90 days and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracerebral hemorrhage (sICH)</measure>
    <time_frame>36 hours</time_frame>
    <description>Proportion of patients with sICH defined as parenchymal hemorrhage type 2 (PH2), subarachnoid hemorrhage, and/or intraventricular hemorrhage within 36 of treatment, combined with a neurological deterioration of ≥4 points on the NIHSS from baseline, or leading to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to index stroke within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality due to index stroke within 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>All-cause mortality within 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) 5-6 at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients with Modified Rankin Scale (mRS) 5-6 at 90 days (severe disability or death)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stage 1- Intermediate outcome</measure>
    <time_frame>Initial angiogram (day 0)</time_frame>
    <description>Proportion of patients achieving partial or complete recanalization of the basilar artery on initial digital subtraction angiography (DSA) prior to thrombectomy or repeat CT Angiography (if DSA not performed) without symptomatic intracerebral hemorrhage (sICH). Partial or complete recanalization is defined as reperfusion of ≥50% of the affected territory or absence of retrievable thrombus.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">688</enrollment>
  <condition>Basilar Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Intravenous tenecteplase (TNK)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care (which may include intravenous Alteplase)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.</description>
    <arm_group_label>Intravenous tenecteplase (TNK)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Care (which may include intravenous Alteplase)</intervention_name>
    <description>Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.</description>
    <arm_group_label>Standard Care (which may include intravenous Alteplase)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with posterior circulation ischemic stroke symptoms due to partial&#xD;
             or complete basilar artery occlusion within 24 hours from symptom onset (or clinical&#xD;
             deterioration/coma) or the time the patient was last known to be well.&#xD;
&#xD;
          -  Patient's age is ≥18 years&#xD;
&#xD;
          -  Presence of basilar artery occlusion, proven by CT Angiography or MR Angiography.&#xD;
             Basilar artery occlusion is defined as 'potentially retrievable' occlusion at the&#xD;
             basilar artery. This can be a partial or complete occlusion.&#xD;
&#xD;
          -  Premorbid mRS ≤3 (independent function or requiring only minor domestic assistance and&#xD;
             able to manage alone for at least 1 week).&#xD;
&#xD;
          -  Local legal requirements for consent have been satisfied.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intracerebral hemorrhage (ICH) or other diagnosis (e.g. tumour) identified by baseline&#xD;
             imaging.&#xD;
&#xD;
          -  Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) &lt;7 on&#xD;
             non-contrast CT, CT Angiography source images or DWI MRI.&#xD;
&#xD;
          -  Significant cerebellar mass effect or acute hydrocephalus.&#xD;
&#xD;
          -  Established frank hypodensity on non-contrast CT indicating subacute infarction.&#xD;
&#xD;
          -  Bilateral extensive brainstem ischemia.&#xD;
&#xD;
          -  Strong suspicion of underlying intracranial atherosclerotic disease (e.g diffuse&#xD;
             arterial calcifications, basilar stenosis) or suspected dissection requiring immediate&#xD;
             neuro-interventional procedure likely to involve intracranial stenting.&#xD;
&#xD;
          -  Pre-stroke mRS of ≥4 (indicating moderate to severe previous disability).&#xD;
&#xD;
          -  Other standard contraindications to intravenous thrombolysis.&#xD;
&#xD;
          -  Contraindication to imaging with contrast agents.&#xD;
&#xD;
          -  Clinically evident pregnant women.&#xD;
&#xD;
          -  Current participation in another research drug treatment protocol.&#xD;
&#xD;
          -  Known terminal illness such that the patients would not be expected to survive a year.&#xD;
&#xD;
          -  Planned withdrawal of care or comfort care measures.&#xD;
&#xD;
          -  Any condition that, in the judgment of the investigator could impose hazards to the&#xD;
             patient if study therapy is initiated or affect the participation of the patient in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Campbell</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Melbourne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fana Alemseged</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fana Alemseged, MD, PhD</last_name>
    <phone>+6193424424</phone>
    <email>Fana.Alemseged@unimelb.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy McDonald, BN</last_name>
    <phone>+6193424424</phone>
    <email>Amy.McDonald@mh.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bankstown-Lidcombe Hospital</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Megan Miller</last_name>
    </contact>
    <investigator>
      <last_name>Fintan O' Rourke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle Russell</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Garcia Esperon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Megan Miller</last_name>
    </contact>
    <investigator>
      <last_name>Mark Parsons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Berzenn Urbi</last_name>
    </contact>
    <investigator>
      <last_name>Peter Bailey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Cranefield</last_name>
    </contact>
    <investigator>
      <last_name>Timothy Kleinig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrea Moore</last_name>
    </contact>
    <investigator>
      <last_name>Geoffrey Cloud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Dennis Young</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Thijs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Tessa Busch</last_name>
    </contact>
    <investigator>
      <last_name>Philip Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie Veronic Hervet</last_name>
    </contact>
    <investigator>
      <last_name>Shaloo Singhal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Amy McDonald, BN</last_name>
      <phone>+619342 4424</phone>
      <email>amy.mcdonald@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Bruce Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Sherisse Celestino</last_name>
    </contact>
    <investigator>
      <last_name>Tissa Wijeratne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>basilar artery occlusion</keyword>
  <keyword>Stroke</keyword>
  <keyword>Tenecteplase</keyword>
  <keyword>Tissue Plasminogen Activator</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient data will be uploaded to the Virtual Stroke Trials Archive 2 years after the publication of the primary manuscript. Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.</ipd_description>
    <ipd_time_frame>2 years after the publication of the primary manuscript.</ipd_time_frame>
    <ipd_access_criteria>Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.</ipd_access_criteria>
    <ipd_url>https://www.virtualtrialsarchives.org/vista/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

